The Dermatology Drug Development Summit Europe returns for its 6th year as the premier industry forum dedicated to advancing next-generation immunodermatology therapies. With regulatory breakthroughs reshaping the landscape-such as Eli Lilly’s IL-13 inhibitor and LEO Pharma’s topical JAK-I-2024 was a pivotal year for the industry to accelerate innovation.
Join 80+ senior leaders from Sanofi, Alys Pharmaceuticals, Moonlake Immunotherapeutics, and more to ensure 2025 breaks new records for the industry!
Get stuck into topics such as:
- Explore novel clinical and preclinical candidate data to produce best-in-class drugs for diverse indications
- Understand contemporary indication expansion strategies to maximise the value of your pipeline and diversify your immuno-inflammatory portfolio
- Collaborate with peers to accelerate trial timelines, optimize endpoint strategies, and enhance clinical data quality to fast track regulatory approval
Brochure: https://go.evvnt.com/2918020-3?pid=1356
